Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

NCT04989816 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG: Trastuzumab Deruxtecan

Sponsor

AstraZeneca

Collaborators

[object Object]